433940-03-5

Upstream product

• 98349-22-5 2,4,5-trifluorobenzonitrile 
• 433940-02-4 2,5-difluoro-4-formylbenzonitrile 

Downstream Products

• 1245651-19-7 4-(bromomethyl)-2,5-difluorobenzonitrile 
• 1355636-82-6 4-((3,4-dichlorophenoxy)methyl)-2,5-difluorobenzonitrile 
• 1355636-83-7 4-((3,4-dichlorophenoxy)methyl)-2,5-difluorobenzamide 
• 1355631-48-9 4-((3,4-dichlorophenoxy)methyl)-2,5-difluoro-N-(methylsulfonyl)benzamide diethylamine salt 
• 433940-04-6 (iv)-4-Cyano-2,5-difluorobenzyl methanesulfonate 

Relevant academic research and scientific papers

CHEMICAL COMPOUNDS

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein X, Ar1, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.